Author | Year | Patient (n,gender) | Peripheral precocious puberty | Durationa | Central precocious puberty | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SI (months) | CA (years) | BA advancement (years) | Sex steroid T(ng/ml) E (pg/ml) | Etiology | Therapy | Outcome | CA | BA | Sex steroid hormone | Therapy | ||||
Pescovitz OH | 1984 | 3 M, 1 F | N/A | 4.88 ± 0.74 | N/A | N/A | CAH | hydrocortisone and fludrocortisone | N/A | 2.12 ± 1.38 year b | 6.75 ± 0.83 | 10.5–13.5 | T 274 ± 60 E 40 ± 15 | LHRHa |
Criscuolo T | 1985 | 1 M | 12 | 6 | 6.00 | T 270–360 | Leydig cell tumor | cyproterone acetate→surgery | regress | 6 months after surgery | 7.50 | N/A | T 280 | cyproterone acetate |
Pescovitz OH | 1985 | 1 F | 36 | 4.5 | 6.50 | T 322 | Adrenal tumor | adrenalectomy | regress | 4 months after surgery | 4.80 | 12.00 | E 32.0 | LHRHa |
Schmidt H | 1998 | 1 F | N/A | N/A | N/A | N/A | McCune-Albright syndrome | N/A | N/A | N/A | 6 | 11 | E 15.6 | GnRHa |
Ghazi AA | 2001 | 1 M | 11 | 6.5 | 6.50 | T 887 | Leydig cell tumor | orchidectomy | regress | 3 months after surgery | 6.8 | N/A | T 141.3 | medroxyprogesterone, cyproterone acetate → LHRH |
Bajpai A | 2006 | 1 M | 3 | 2.5 | 5.90 | T 224 | CAH | hydrocortisone and spironolactone | N/A | 3 yr | 5.2 | 15 | N/A | GnRHa |
Jeha GS | 2006 | 1 M | 36 | 4.5 | 5.50 | T 254 | FMPP | testolactone, spironolactone, flutamide | progress | 18months | 6 | 13 | T 225 | GnRHa(Lupron Depot) |
Almeida MQ | 2008 | 4 M | N/A | 4.13 ± 2.21 | 3.25 ± 1.47 | T 196–266 | FMPP | cyproterone acetate or ketoconazole | N/A | N/A | N/A | N/A | N/A | GnRHa |
Kiepe D | 2008 | 1 M | 24 | 6.7 | 5.30 | T 312 | Leydig cell tumor | surgery | regress | 1 year | 7.7 | 13.5 | T 47 | GnRHa |
Bas F | 2009 | 1 F | 24 | 2.5 | N/A | E 90 | Overy granulosa cell tumor | surgery | progress | 7 months after surgery | 3.1 | 7 | E 30 | GnRHa |
Miyoshi Y | 2009 | 1 M | 18 | 6.5 | 5 | T 218 | Adrenal tumor | surgery | regress | 2 months after the operation | 6.80 | N/A | T 92 | GnRHa |
Lignitz S | 2011 | 1 M | 12 | 7 | 5.50 | T 144 | Leydig cell tumor | surgery | regress | 2 months after the operation | 7.2 b | N/A | T 201 | GnRHa |
Olivier P | 2012 | 1 M | 36 | 9 | 4.50 | T 268 | Leydig cell tumor | surgery | testosterone decreased | 1 month after surgery | 9.1b | N/A | T 37 | N/A |
Santos-Silva R | 2013 | 1 M | 12 | 8 | 4.00 | T 148 | Leydig cell tumor | surgery | progress | 2 months after surgery | 8.2b | N/A | T 245 | GnRHa |
Güven A, | 2015 | 5 M, 5 F | N/A | 6.18 ± 2.1 | 4.53 ± 1.92 | T 1.21–625 E2 20-40.1 | CAH | hydrocortisone, mineralocorticoid | N/A | 0.82 ± 0.54 years | 6.78 ± 1.8 | 11.2 ± 1.7 | N/A | GnRHa |
Kim MS | 2015 | 1 M | 3 | 8 | 1.50 | T 382 | Adrenal tumor | surgery | regress | 2 months after the operation | 8.2 | N/A | T 334 | GnRHa |
Verrotti A | 2015 | 2 M | 4,6 | 7.5,7.7 | 2.3,3.3 | T 158, | Leydig cell tumor | surgery | regress | 4 months after surgery | 7.8-8.0 | 12.5, 12 | T 178, 210 | GnRHa |
Sahana PK | 2016 | 1 M | 5.4 | N/A | N/A | N/A | CAH | hydrocortisone | N/A | N/A | 6.5 | 12 | T 910 | LHRHa |
Ersoy B | 2017 | 1 F | 4 | 4 | 5.00 | E 34.6 T 67.22 | Adrenal tumor | surgery | progress | 24 months after surgery | 6 | 10.50 | E2 20 | GnRHa |
Dayal D | 2018 | 4 F, 1 M | 14 | 3.6 ± 0.74 | 3.2 ± 1.3 | N/A | CAH | hydrocortisone and fludrocortisone | N/A | N/A | 4.7 ± 1.2 | N/A | N/A | GnRHa |
Goyal A | 2019 | 1 M | 8 | 7 | 6.00 | T 1190 | Adrenal tumor | surgery | regress | 6 months after surgery | 7.5b | N/A | T 72.9 | GnRHa |
Stecchini MF | 2019 | 4 F, 3 M | 6 ≥ 48 months 6 < 48 months | 4 ≥ 48 months 3 < 48 months | 5 Advanced 1 Not advanced | T 381 | Adrenal tumor | surgery combined with chemotherapy or radiotherapy | N/A | N/A | N/A | N/A | N/A | GnRHa(2 F, 1 M) |
Singhania P | 2022 | 1 M | 4–6 | 6 | 6.00 | T 293 | Leydig cell tumor | surgery | regress | 4 weeks after surgery | 6.1b | N/A | T 28.4 | GnRHa |
Gaikwad PM | 2022 | 1 F | 30 | 5.5 | N/A | E 22.1 | Overy granulosa cell tumor | surgery and chemotherapy | N/A | 18 months after surgery | 7 | 11 | E 11 | GnRHa |
Cattoni A | 2022 | 1 M | 4 | 6.2 | N/A | 6.85 | mature teratomatous and germinoma | bicalutamide and anastrozole →surgery→chemotherapy and radiotherap | progress | 8 months after surgery | 8.00 | N/A | N/A | GnRHa |